Sale

Rheumatoid Arthritis Therapeutics Market

Rheumatoid Arthritis Therapeutics Market Size, Share, Trends: By Drug Class: Biologics, Non-Biologics; By Sales Channel: Prescription, Over The Counter (OTC), Others; By Route of Administration: Oral, Parenteral; By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Rheumatoid Arthritis Therapeutics Market Size

The rheumatoid arthritis therapeutics market was valued at USD 29506.4 million in 2023, driven by the increasing prevalence of rheumatoid arthritis across the globe. The market is expected to grow at a CAGR of 4.60% during the forecast period of 2024-2032, with the values likely to rise from USD 30.864 billion in 2024 to USD 44228.4 million by 2032.

 

Rheumatoid Arthritis Therapeutics Market Outlook

  • A significant driver of the market is the increasing prevalence of rheumatoid arthritis and the growing aging population.
  • One of the major market trends is the surge in clinical trials of new and advanced rheumatoid arthritis medications which are anticipated to enhance patient outcomes and stimulate market expansion.
  • There is a growing market demand for biologics due to their ability to target specific parts of the immune system responsible for inflammation and prevent long-term disability associated with rheumatoid arthritis.

 

Rheumatoid Arthritis Therapeutics Market Overview

Rheumatoid arthritis (RA) is an auto-immune disorder, a condition in which a person's immune system identifies one's cellular and organ makeup as antigenic entities, resulting in the synthesis of antibodies against one's own body. The disease tends to attack the linings of the joints leading to bone abrasion, joint inflammation, and severe pain. If left untreated, the disease could spread across various organs, which initially affect the joints of fingers and toes. A surge in obesity rates, increasing awareness concerning rheumatic disorders, and the rising geriatric population have significantly contributed to the market growth. Additionally, the rise in generic drug approvals and growth in clinical trials reflects the ongoing expansion of the market.

 

Rheumatoid Arthritis Therapeutics Market Growth Drivers

Growing Prevalence of Rheumatoid Arthritis Drives the Market Demand

 

A significant driver in the market includes the growing prevalence of the disease. Recent data reveals that around 1.5 million people in the United States are affected by rheumatoid arthritis. Moreover, females are reported to be nearly three times more likely to develop the autoimmune condition as compared to males. Research has shown that early treatment can put the disease into remission, reflecting the importance of effective therapeutics to manage the condition. Thus, with the rising cases of the disease, the market demand for these drugs is expected to witness a rise. Further, the increasing aging population which is at a higher risk of developing the disorder is poised to influence the market landscape.

 

Rheumatoid Arthritis Therapeutics Market Trends

Rising Entry of Generic Drugs Supports the Market Expansion

 

In August 2023, an Indian multinational pharmaceutical company Zydus Lifesciences Limited received the United States US Food and Drug Administration's (FDA) approval to manufacture and market its generic Indomethacin suppositories (50 mg strength), a non-steroidal and anti-inflammatory drug used for the treatment of moderate to severe rheumatoid arthritis. The FDA also granted a 180-day competitive generic therapy (CGT) exclusivity to market the generic treatment drug as it deemed there is inadequate generic competition for the drug in the United States market. The rise in the approval of generic therapeutics indicated for rheumatoid arthritis is likely to improve the accessibility of treatment alternatives to the growing patient pool, which is projected to bolster the market growth in the forecast period.

 

Surge in Clinical Trials of Novel Therapies to Meet the Rising Rheumatoid Arthritis Therapeutics Market Demand

 

One of the major market trends is the growth in clinical trials of new and advanced rheumatoid arthritis medications which are anticipated to enhance patient outcomes and stimulate market expansion. In October 2023, a United States-based biotechnology company Rise Therapeutics revealed that the regulatory agency FDA has accepted its investigational new drug (IND) application that will allow initiation of the Phase I clinical trial of R-2487 intended for the treatment of rheumatoid arthritis. In the single and repeat-dose clinical study enrolling 36 subjects, the cellular immunotherapy R-2487 will be assessed for tolerability, drug exposure, safety, and clinical activity. It is reported that the clinical activity of R-2487 will be evaluated by measuring improvement in rheumatoid arthritis disease severity and other biomarkers. The development of such oral immunotherapy treatments that can facilitate ease of delivery of protein-based biologics therapy and are available at reduced costs are projected to positively impact the market dynamics.

 

Rising Preference for Combination Therapies is Projected to Boost Rheumatoid Arthritis Therapeutics Market Size

 

Treatments for rheumatoid arthritis manage inflammation in the affected patients and can ease associated symptoms like pain and stiffness. However, sometimes a single drug is not sufficient to treat this autoimmune disease. In such cases, patients are prescribed with more than one drug to effectively control the symptoms. For example, a treatment that combines ethotrexate with leflunomide or methotrexate with sulfasalazine is reported to be the most effective two-drug combinations of conventional disease-modifying antirheumatic drugs (DMARDs) . The rising demand for combination therapies due to their ability to provide better clinical benefits is anticipated to fuel the market size.

 

Advances in Personalized Medicine is Likely to Elevate Rheumatoid Arthritis Therapeutics Market Value

 

The rising advancements in personalized treatment approaches supported by robust research initiatives is resulting in tailored therapies that can improve patient outcomes. Biomarkers are increasingly employed as key tools in the development of personalized medicine towards rheumatoid arthritis to accurately predict the patient’s disease phenotype and response to treatment. Further, the growing innovation in omic technologies and clinical study design is expected to accelerate rheumatoid biomarker discovery, which is likely to amplify the demand for precision medicine, thereby stimulating market growth.

 

Rheumatoid Arthritis Therapeutics Market Segmentation

Market Breakup by Product Type

  • Biologics
  • Non-Biologics
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
    • Others

 

Market Breakup by Sales Type

  • Prescription
  • Over The Counter (OTC)
  • Others

 

Market Breakup by Route of Administration

  • Oral
  • Parenteral

 

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online

 

Market Breakup by End User

  • Hospitals & Clinics 
  • Research and Academic Laboratories 
  • Others

 

Market Breakup by Region

  • United States
  • EU-4 and United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
  • Japan
  • India

 

Rheumatoid Arthritis Therapeutics Market Share

Market Segmentation Based on Product Type is Poised to Propel Market Growth

 

The market segmentation by product type includes biologics and non-biologics. Biologics include advanced drugs such as tumor necrosis factor (TNF) inhibitors and interleukin inhibitors. These medications target specific parts of the immune system responsible for inflammation in rheumatoid arthritis. Non-biologics are further subdivided into non-steroidal anti-inflammatory drugs (NSAIDs), synthetic disease-modifying antirheumatic drugs (SDMARDs) like methotrexate, and other medications including corticosteroids that help manage symptoms or certain complications. There is a growing demand for biologics due to their ability to prevent long-term disability associated with the disease is likely to augment the rheumatoid arthritis therapeutics market demand.

 

Prescription and Over-the-Counter Rheumatoid Arthritis Therapeutics are Witnessing Market Demand

 

Based on the sales type, the market comprises prescription, and over-the-counter rheumatoid arthritis therapeutics, among others. Prescription drugs hold a significant share, including majority of rheumatoid arthritis therapies that require medical oversight due to their potential side effects. Over-the-counter (OTC) drugs, mainly some non-steroidal anti-inflammatory (NSAIDs), are available without a prescription to manage pain and inflammation. Advil and Aleve are some examples of widely used rheumatoid arthritis drugs that are sold over-the-counter.

 

Rheumatoid Arthritis Therapeutics Market Analysis by Region

The market is witnessing colossal growth in United States due to the highest reported disease cases. Moreover, the increasing awareness and health consciousness among people have significantly contributed to the dominant share of the regional market. Also, the increasing budget allocation in the arena of rheumatoid arthritis therapeutics equally raises its market value.

 

EU-4 and the United Kingdom has seen significant propellants in the form of innovative drugs, advanced healthcare alternatives to grapple with the disease, and an increment in cases. In the Asia Pacific region, Japan, and India’s market growth is catalyzed by the improvement in healthcare infrastructure, increasing awareness, and growing adoption of biologics.

 

rheumatoid arthritis therapeutics market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Leading Players in the Rheumatoid Arthritis Therapeutics Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Pfizer Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • UCB S.A.
  • Gilead Sciences, Inc.
  • Boehringer Ingelheim GmbH
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie
  • Eli Lilly and Company
  • Celgene Corporation

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Sales Channel
  • Route of Administration
  • Distribution Channel
  • End User
  • Region
Breakup by Drug Class
  • Biologics
  • Non-Biologics
Breakup by Sales Channel
  • Prescription
  • Over The Counter (OTC)
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online
Breakup by End User
  • Hospitals & Clinics
  • Research and Academic Laboratories
  • Others
Breakup by Region
  • United States 
  • EU-4 and United Kingdom 
  • Japan 
  • India
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Amgen Inc. 
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim GmbH
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie.
  • Eli Lilly and Company
  • UCB S.A.
  • Gilead Sciences, Inc.
  • Celgene Corporation

 

Key Questions Answered in the Rheumatoid Arthritis Therapeutics Market Report

  • What was the rheumatoid arthritis therapeutics market value in 2023?
  • What is the rheumatoid arthritis therapeutics market forecast outlook for 2024-2032?
  • What are the regional markets covered in the EMR report?
  • What is market segmentation based on product type?
  • What is the market breakup based on sales type?
  • What is the market breakup by route of administration?
  • What are the various distribution channels present in the market?
  • What are the major end users in the market?
  • What are the major factors aiding the rheumatoid arthritis therapeutics market demand? 
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints? 
  • Which regional market is expected to lead the market share in the forecast period? 
  • Which country is expected to experience expedited growth during the forecast period? 
  • How does the prevalence and incidence of rheumatoid arthritis affect the market landscape?
  • What are the major rheumatoid arthritis therapeutics market trends?
  • How does the rise in the geriatric population impact the market size?
  • Which product type will dominate the market share? 
  • Which sales type is expected to have a high market value in the coming years?
  • Which route of administration will experience the highest demand in the market segment?
  • Which distribution channel is poised to cover a major market share?
  • Which end user is anticipated to drive market growth?
  • Who are the key players involved in the rheumatoid arthritis therapeutics market?
  • What clinical trials are undergoing in the market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Rheumatoid Arthritis Therapeutics Market Overview - 8 Major Markets

    3.1    Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023) 
    3.2    Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
4    Rheumatoid Arthritis – Disease Overview
    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Rheumatoid Arthritis Epidemiology Analysis – 8 Major Markets
    6.1    8MM Epidemiology Scenario Overview (2017-2032)
    6.2    United States Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
    6.3    EU-4 and United Kingdom Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
        6.3.1    Germany Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
        6.3.2    France Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
        6.3.3    Italy Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
        6.3.4    Spain Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
        6.3.5    United Kingdom Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
    6.4    Japan Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032) 
    6.5    India Rheumatoid Arthritis Epidemiology Scenario and Forecast (2017-2032)
7    Rheumatoid  Arthritis Therapeutics Market Landscape* - 8 Major Markets
    7.1    Rheumatoid Arthritis Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Rheumatoid Arthritis Therapeutics: Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Sales Channel
        7.2.3    Analysis by Route of Administration
8    Rheumatoid Arthritis Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost  of Treatment
10    Rheumatoid Arthritis Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Rheumatoid Arthritis Therapeutics Market Segmentation - 8 Major Markets
    11.1    Rheumatoid Arthritis Therapeutics Market by Drug Class
        11.1.1    Market Overview
        11.1.2    Biologics
        11.1.3    Non-Biologics
            11.1.3.1    Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 
            11.1.3.2    Disease-Modifying Antirheumatic Drugs (DMARDs)
            11.1.3.3    Others
    11.2    Rheumatoid Arthritis Therapeutics Market by Sales Channel
        11.2.1    Market Overview
        11.2.2    Prescription
        11.2.3    Over The Counter (OTC)
        11.2.4    Others
    11.3    Rheumatoid Arthritis Therapeutics Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Parenteral
    11.4    Rheumatoid Arthritis Therapeutics Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacy
        11.4.3    Retail Pharmacy
        11.4.4    Online
    11.5    Rheumatoid Arthritis Therapeutics Market by End User
        11.5.1    Market Overview
        11.5.2    Hospitals & Clinics
        11.5.3    Research and Academic Laboratories
        11.5.4    Others
    11.6    Rheumatoid Arthritis Therapeutics Market by Region
        11.6.1    Market Overview
        11.6.2    United States 
        11.6.3    EU-4 and United Kingdom 
            11.6.3.1    Germany 
            11.6.3.2    France 
            11.6.3.3    Italy 
            11.6.3.4    Spain 
            11.6.3.5    United Kingdom 
        11.6.4    Japan 
        11.6.5    India 
12    United States  Rheumatoid Arthritis Therapeutics Market
    12.1    United States Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023) 
    12.2    United States Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
    12.3    United States Rheumatoid Arthritis Therapeutics Market by Drug Class
    12.4    United States Rheumatoid Arthritis Therapeutics Market by Sales Channel
13    EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market
    13.1    EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023) 
    13.2    EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
    13.3    EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market by Drug Class
    13.4    EU4 and United Kingdom Rheumatoid Arthritis Therapeutics Market by Sales Channel
14    Japan Rheumatoid Arthritis Therapeutics Market
    14.1    Japan Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023) 
    14.2    Japan Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
    14.3    Japan Rheumatoid Arthritis Therapeutics Market by Drug Class
    14.4    Japan Rheumatoid Arthritis Therapeutics Market by Sales Channel
15    India Rheumatoid Arthritis Therapeutics Market
    15.1    India Rheumatoid Arthritis Therapeutics Market Historical Value (2017-2023) 
    15.2    India Rheumatoid Arthritis Therapeutics Market Forecast Value (2024-2032)
    15.3    India Rheumatoid Arthritis Therapeutics Market by Drug Class
    15.4    India Rheumatoid Arthritis Therapeutics Market by Sales Channel
16    Regulatory  Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    India CDSCO
        16.1.4    Japan PMDA
        16.1.5    Others
17    Patent Analysis
    17.1    Analysis by Type of Patent
    17.2    Analysis by Publication year
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Patent Age
    17.5    Analysis by CPC Analysis
    17.6    Analysis by Patent Valuation 
    17.7    Analysis by Key Players
18    Grants  Analysis
    18.1    Analysis by year
    18.2    Analysis by Amount Awarded
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Grant Application
    18.5    Analysis by Funding Institute
    18.6    Analysis by NIH Departments
    18.7    Analysis by Recipient Organization 
19    Clinical Trials Analysis
    19.1     Analysis by Trial Registration Year
    19.2    Analysis by Trial Status
    19.3    Analysis by Trial Phase
    19.4    Analysis by Therapeutic Area
    19.5    Analysis by Geography
20    Funding  and Investment Analysis
    20.1    Analysis by Funding Instances
    20.2    Analysis by Type of Funding
    20.3    Analysis by Funding Amount
    20.4    Analysis by Leading Players
    20.5    Analysis by Leading Investors
    20.6    Analysis by Geography
21    Partnership and Collaborations Analysis
    21.1    Analysis by Partnership Instances
    21.2    Analysis by Type of Partnership
    21.3    Analysis by Leading Players
    21.4    Analysis by Geography
22    Supplier  Landscape
    22.1    Market Share of Top 5 Companies
    22.2    Pfizer Inc.
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications
    22.3    Amgen Inc. 
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    Bristol-Myers Squibb Company 
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    F. Hoffmann-La Roche Ltd
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Boehringer Ingelheim GmbH
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    Novartis International AG
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    Regeneron Pharmaceuticals, Inc.
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    AbbVie.
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Eli Lilly and Company
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
    22.11    UCB S.A.
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisitions
        22.11.5    Certifications
    22.12    Gilead Sciences, Inc.
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Mergers and Acquisitions
        22.12.5    Certifications
    22.13    Celgene Corporation
        22.13.1    Financial Analysis
        22.13.2    Product Portfolio
        22.13.3    Demographic Reach and Achievements
        22.13.4    Mergers and Acquisitions
        22.13.5    Certifications
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER